Exploring Diabetic Retinopathy Patterns in Saudi Arabia: Gender and Diabetes Type Comparison
Abstract
:1. Introduction
2. Material and Methods
2.1. Design and Study Population
2.2. Procedure and Measurements
2.3. Statistical Methods
3. Results
3.1. General Characteristics
3.2. Predictors of Diabetic Retinopathy
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
References
- International Diabetes Federation. IDF Diabetes Atlas. 2015. Available online: https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf (accessed on 1 September 2021).
- Al-Sinani, S.; Al-Mamari, A.; Woodhouse, N.; Al-Shafie, O.; Amar, F. Complications and associated conditions among Omani type 2 diabetes patients at Sultan Qaboos University Hospital, Muscat, Oman. J. Fam. Med. 2014, 1, 1–6. [Google Scholar]
- Copeland, K.C.; Zeitler, P.; Geffner, M.; Guandalini, C.; Higgins, J.; Hirst, K.; Kaufman, F.R.; Linder, B.; Marcovina, S.; McGuigan, P.; et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: The today cohort at baseline. J. Clin. Endocrinol. Metab. 2011, 96, 159–167. [Google Scholar] [CrossRef] [PubMed]
- Arun, C.S.; Al-Bermani, A.; Stannard, K.; Taylor, R. Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age population. Diabet. Med. 2009, 26, 489–492. [Google Scholar] [CrossRef] [PubMed]
- Liew, G.; Michaelides, M.; Bunce, C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open 2014, 4, e004015. [Google Scholar] [CrossRef] [PubMed]
- Fenwick, E.K.; Xie, J.; Ratcliffe, J.; Pesudovs, K.; Finger, R.P.; Wong, T.Y.; Lamoureux, E.L. The impact of diabetic retinopathy and diabetic macular oedema on health-related quality of life in type 1 and type 2 diabetes. Investig. Ophthalmol. Vis. Sci. 2012, 53, 677–684. [Google Scholar] [CrossRef]
- Yau, J.W.Y.; Rogers, S.L.; Kawasaki, R.; Lamoureux, E.L.; Kowalski, J.W.; Bek, T.; Chen, S.-J.; Dekker, J.M.; Fletcher, A.; Grauslund, J.; et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care 2012, 35, 556–564. [Google Scholar] [CrossRef]
- Al-Rubeaan, K.; Abu El-Asrar, A.M.; Youssef, A.M.; Subhani, S.N.; Ahmad, N.A.; Al-Sharqawi, A.H.; Alguwaihes, A.; Alotaibi, M.S.; Al-Ghamdi, A.; Ibrahim, H.M. Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: A Saudi National Diabetes Registry-based study. Acta Ophthalmol. 2014, 93, e140–e147. [Google Scholar] [CrossRef]
- Abu El-Asrar, A.M.; Al-Rubeaan, K.A.; Al-Amro, S.A.; Moharram, O.A.; Kangave, D. Retinopathy as a predictor of other diabetic complications. Int. Ophthalmol. 2001, 24, 1–11. [Google Scholar] [CrossRef]
- Venkatesh, P.; Tibrewal, S.; Bhowmik, D.; Tripathi, M.; Ramakrishnan, S.; Vashist, N.; Vohra, R.; Garg, S. Prevalence of systemic co-morbidities in patients with various grades of diabetic retinopathy. Indian J. Med. Res. 2014, 140, 77. [Google Scholar]
- Galosi, E.; Hu, X.; Michael, N.; Nyengaard, J.R.; Truini, A.; Karlsson, P. Redefining distal symmetrical polyneuropathy features in type 1 diabetes: A systematic review. Acta Diabetol. 2021, 59, 1–19. [Google Scholar] [CrossRef]
- Hajas, G.; Kissova, V.; Tirpakova, A. A 10-yr follow-up study for the detection of peripheral neuropathy in young patients with type 1 diabetes. Pediatr. Diabetes 2016, 17, 632–641. [Google Scholar] [CrossRef]
- Gujarati, D.N.; Porter, D.C. Essentials of Econometrics, 5th ed.; Irwin/McGraw-Hill: Singapore, 2021. [Google Scholar]
- Lee, W.J.; Sobrin, L.; Lee, M.J.; Kang, M.H.; Seong, M.; Cho, H. The Relationship Between Diabetic Retinopathy and Diabetic Nephropathy in a Population-Based Study in Korea (KNHANES V-2, 3). Investig. Ophthalmol. Vis. Sci. 2014, 55, 6547–6553. [Google Scholar] [CrossRef]
- Ahmed, R.A.; Khalil, S.N.; Al-Qahtani, M.A. Diabetic retinopathy and the associated risk factors in diabetes type 2 patient s in Abha, Saudi Arabia. J. Fam. Community Med. 2016, 23, 18. [Google Scholar] [CrossRef] [PubMed]
- Alwin Robert, A.; Al Dawish, M.A. Microvascular complications among patients with diabetes: An emerging health problem in Saudi Arabia. Diabetes Vasc. Dis. Res. 2019, 16, 227–235. [Google Scholar] [CrossRef] [PubMed]
- Miller, R.G.; Mahajan, H.D.; Costacou, T.; Sekikawa, A.; Anderson, S.J.; Orchard, T.J. A Contemporary Estimate of Total Mortality and Cardiovascular Disease Risk in Young Adults With Type 1 Diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2016, 39, 2296–2303. [Google Scholar] [CrossRef] [PubMed]
- Gadkari, S.S.; Maskati, Q.B.; Nayak, B.K. Prevalence of diabetic retinopathy in India: The All India Ophthalmological Society Diabetic Retinopathy Eye Screening Study 2014. Indian J. Ophthalmol. 2016, 64, 38–44. [Google Scholar] [CrossRef]
- Karlberg, C.; Falk, C.; Green, A.; Sjølie, A.K.; Grauslund, J. Proliferative retinopathy predicts nephropathy: A 25-year follow-up study of type 1 diabetic patients. Acta Diabetol. 2011, 49, 263–268. [Google Scholar] [CrossRef]
- Murphy, R.; Jiang, Y.; Booth, M.; Babor, R.; MacCormick, A.; Hammodat, H.; Beban, G.; Barnes, R.M.; Vincent, A.L. Progression of diabetic retinopathy after bariatric surgery. Diabet. Med. 2015, 32, 1212–1220. [Google Scholar] [CrossRef]
- Al Ghamdi, A.H.; Rabiu, M.; Hajar, S.; Yorston, D.; Kuper, H.; Polack, S. Rapid assessment of avoidable blindness and diabetic retinopathy in Taif, Saudi Arabia. Br. J. Ophthalmol. 2012, 96, 1168–1172. [Google Scholar] [CrossRef]
- Hajar, S.; Al Hazmi, A.; Wasli, M.; Mousa, A.; Rabiu, M. Prevalence and causes of blindness and diabetic retinopathy in Southern Saudi Arabia. SciVee 2015, 36, 449–455. [Google Scholar] [CrossRef]
- El-Bab, M.F.; Shawky, N.; Al-Sisi, A.; Akhtar, M. Retinopathy and risk factors in diabetic patients from Al-Madinah Al-Munawarah in the Kingdom of Saudi Arabia. Clin. Ophthalmol. 2012, 6, 269. [Google Scholar] [CrossRef] [PubMed]
Panel A: Continuous Variables | ||||||
---|---|---|---|---|---|---|
Variables | Mean | SD | Median | Skewness | Kurtosis | Number of Observations |
Age | 47.319 | 17.477 | 51.000 | −0.196 | 2.202 | 504 |
BMI | 30.390 | 6.832 | 29.810 | 0.347 | 3.228 | 459 |
DM duration | 11.910 | 6.370 | 11.000 | 0.705 | 3.012 | 410 |
Hyperglycemia | 8.922 | 2.129 | 8.600 | 1.211 | 5.380 | 502 |
Panel B: Dichotomous Variables | ||||||
Variables | Caption | Percent | Mean | SD | The Overall Number of Observations | |
Gender | Male | 40.71% | 0.593 | 0.492 | 507 | |
Female | 59.29% | |||||
DLP | No | 28% | 1.613 | 0.488 | 506 | |
Yes | 44.29% | |||||
Hypertension | No | 33.14% | 1.542 | 0.499 | 507 | |
Yes | 39.29% | |||||
Nephropathy | No | 51.29% | 1.286 | 0.452 | 503 | |
Yes | 20.57% | |||||
Neuropathy | No | 58.71% | 1.186 | 0.390 | 505 | |
Yes | 13.43% | |||||
DM type | Type one | 19.57% | 1.730 | 0.445 | 507 | |
Type Two | 52.86% | |||||
DR Stages | No DR | 51.43% | 1.712 | 1.257 | 507 | |
NPDR | 4.43% | |||||
Mild NPDR | 7.71% | |||||
Severe NPDR | 3.71% | |||||
PDR | 5.14% |
Variables | (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) |
---|---|---|---|---|---|---|---|---|
(1) DR Stages | 1.000 | 0.280 ** | 0.199 ** | 0.084 | 0.141 ** | 0.155 ** | 0.192 ** | 0.240 ** |
(2) DM Duration | 0.238 * | 1.000 | 0.091 *** | −0.015 | 0.065 | 0.155 ** | 0.145 ** | 0.166 ** |
(3) DLP | 0.229 * | 0.147 * | 1.000 | 0.318 ** | 0.043 | 0.117 ** | 0.142 ** | 0.580 ** |
(4) BMI | 0.074 | 0.006 | 0.323 * | 1.000 | 0.025 | −0.086 *** | 0.181 ** | 0.306 ** |
(5) Hyperglycemia | 0.080 *** | 0.037 | 0.041 | −0.039 | 1.000 | 0.058 | 0.065 | 0.061 |
(6) Nephropathy | 0.111 ** | 0.163 * | 0.103 ** | −0.056 | 0.080 *** | 1.000 | 0.127 ** | 0.232 ** |
(7) Neuropathy | 0.177 * | 0.172 * | 0.159 * | 0.146 * | 0.056 | 0.152 * | 1.000 | 0.178 ** |
(8) Hypertension | 0.259 * | 0.206 * | 0.574 * | 0.316 * | 0.077 *** | 0.164 * | 0.182 * | 1.000 |
Variables | BMI | DM Duration | Hyperglycemia | DLP | Hypertension | Nephropathy | Neuropathy |
---|---|---|---|---|---|---|---|
dy/dx | dy/dx | dy/dx | dy/dx | dy/dx | dy/dx | dy/dx | |
No DR | 0.0003 | −0.0126 *** | −0.0142 ** | −0.0664 | −0.0970 * | −0.0527 | −0.08342 ** |
(0.0029) | (0.0031) | (0.0067) | (0.0585) | (0.0569) | (0.0430) | (0.0432) | |
NPDR | −0.0001 | 0.0024 *** | 0.0027 ** | 0.0125 | 0.0183 | 0.0099 | 0.01570 * |
(0.0005) | (0.0008) | (0.0013) | (0.0108) | (0.0111) | (0.0084) | (0.009) | |
MILD | −0.0001 | 0.0034 *** | 0.0038 ** | 0.0179 | 0.0262 | 0.0142 | 0.0225 * |
(0.0008) | (0.001) | (0.0019) | (0.0158) | (0.0159) | (0.0119) | (0.0120) | |
SEVERE NPDR | 0.0000 | 0.0018 *** | 0.0020 * | 0.0094 | 0.0137 | 0.0075 | 0.0118 * |
(0.0004) | (0.0007) | (0.0011) | (0.0085) | (0.009) | (0.0061) | (0.0067) | |
PDR | −0.0001 | 0.0050 *** | 0.0057 ** | 0.0266 | 0.0388 * | 0.0211 | 0.033416 * |
(0.0012) | (0.0013) | (0.0029) | (0.0244) | (0.0233) | (0.0176) | (0.0179) |
Baseline Model | Baseline with Gender | Baseline with DM Type | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | T1DM | T2DM | ||||||||||||
Variables | Odds Ratio Values | [95% Conf. Interval Odds] | Odds Ratio Values | [95% Conf. Interval Odds] | Odds Ratio Values | [95% Conf. Interval Odds] | Odds Ratio Values | [95% Conf. Interval Odds] | Odds Ratio Values | [95% Conf. Interval Odds] | |||||
BMI | 0.998 | 0.9649 | 1.0322 | 1.045 | 0.9912 | 1.1030 | 0.971 | 0.9290 | 1.0159 | 1.039 | 0.9533 | 1.1335 | 0.970 | 0.9258 | 1.0175 |
DM Duration | 1.078 *** | 1.0368 | 1.1216 | 1.149 *** | 1.0670 | 1.2371 | 1.0463 ** | 0.9966 | 1.0985 | 1.1313 ** | 1.0390 | 1.2318 | 1.067 *** | 1.0194 | 1.1162 |
Hyperglycemia (HbA1c) | 1.089 ** | 1.0060 | 1.1792 | 1.0772 | 0.8744 | 1.3269 | 1.0810 * | 0.9861 | 1.1850 | 1.0122 | 0.8648 | 1.1847 | 1.162 *** | 1.0381 | 1.3003 |
DLP | 1.490 | 0.7507 | 2.9556 | 2.048 | 0.7284 | 5.7601 | 1.2401 | 0.4869 | 3.1580 | 1.3064 | 0.2598 | 6.5696 | 1.366 | 0.5854 | 3.1892 |
Hypertension | 1.789 * | 0.9099 | 3.5186 | 1.119 | 0.3460 | 3.6220 | 2.7681 ** | 1.1118 | 6.8923 | 1.7128 | 0.2817 | 10.4127 | 1.657 | 0.8160 | 3.3657 |
Nephropathy | 1.372 | 0.8251 | 2.2822 | 1.720 | 0.6606 | 4.4813 | 1.167 | 0.6234 | 2.1837 | 2.896 * | 0.9270 | 9.0463 | 1.137 | 0.6332 | 2.0433 |
Neuropathy | 1.650 * | 0.9816 | 2.7723 | 1.653 | 0.7177 | 3.8083 | 1.837 ** | 0.9387 | 3.5963 | 2.472 | 0.7138 | 8.5613 | 1.478 | 0.8301 | 2.6339 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hussain, S.; AlJohani, N. Exploring Diabetic Retinopathy Patterns in Saudi Arabia: Gender and Diabetes Type Comparison. Diabetology 2023, 4, 490-498. https://0-doi-org.brum.beds.ac.uk/10.3390/diabetology4040042
Hussain S, AlJohani N. Exploring Diabetic Retinopathy Patterns in Saudi Arabia: Gender and Diabetes Type Comparison. Diabetology. 2023; 4(4):490-498. https://0-doi-org.brum.beds.ac.uk/10.3390/diabetology4040042
Chicago/Turabian StyleHussain, Samraa, and Naji AlJohani. 2023. "Exploring Diabetic Retinopathy Patterns in Saudi Arabia: Gender and Diabetes Type Comparison" Diabetology 4, no. 4: 490-498. https://0-doi-org.brum.beds.ac.uk/10.3390/diabetology4040042